Details of the Drug

General Information of Drug (ID: DMUBP9O)

• Drug Name: Voglibose
• Synonyms: Basen; Glustat; Vocarb; Basen OD; A-71100; AO-128; Basen (TN); Basen (Takeda Chemical Industries); Volix (Ranbaxy labs);Voglibose (JP15/USAN/INN); N-(1,3-Dihydroxyprop-2-yl)valiolamine; (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; (1S,2S,3R,4S,5S)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol; 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-D-epi-inositol

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1]
Non-insulin dependent diabetes	5A11	Approved	[2]
Gaucher disease	5C56.0Y	Investigative	[3]

• Therapeutic Class: Hypoglycemic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 2:
  Molecular Weight (mw); 267.28
  Logarithm of the Partition Coefficient (xlogp); -4.1
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 8
  Hydrogen Bond Acceptor Count (hbondacc); 8
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 8.17 mgh/L [4]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 1.38 mg/L [4]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2.5 h [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 4.08 hours [4]
• Chemical Identifiers:
  Formula: C10H21NO7
  IUPAC Name: (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
  Canonical SMILES: C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO
  InChI: InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1
  InChIKey: FZNCGRZWXLXZSZ-CIQUZCHMSA-N
• Cross-matching ID:
  PubChem CID: 444020
  ChEBI ID: CHEBI:32300
  CAS Number: 83480-29-9
  DrugBank ID: DB04878
  TTD ID: D04ZTY
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Intestinal maltase-glucoamylase (MGAM)	TTXWASR	MGA_HUMAN	Inhibitor	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Diabetic complication
• ICD Disease Classification: 5A2Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Intestinal maltase-glucoamylase (MGAM)	DTT	MGAM	4.59E-01	-0.02	-0.24

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013 Sep 2;6:317-25.
• [3] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [4] Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin. Int J Clin Pharmacol Ther. 2015 Feb;53(2):147-53. doi: 10.5414/CP202197.
• [5] Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.